Full-Time

Production Technician

Posted on 10/31/2025

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$27.70/hr

Albany, NY, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Willingness to work a 7 PM -7 AM or a 7 AM - 7 PM shift- this position is for the 7 PM – 7 AM shift.
  • Willingness to train on Days or nights
  • High School diploma or equivalent
  • Must be able to lift maximum of 50 lbs
  • Advanced math skills
  • Ability to follow FDA manufacturing guidelines
  • Communication skills
Responsibilities
  • Complete trainings; Building specific safety, Document training on SOP review, Production Technician Core Competency in the Learning Management System, Site safety and emergency notification and response procedures.
  • Learn and understand common chemical terminology; Reflux, Distillation, Azeptrope, Separations, pH, ML’s, Filtration, Melting Point, Flash point, Vapor Pressure, Density, Boiling Point, Filter Press and Filtrate.
  • Read, understand and interpret Material Safety Data Sheets.
  • Understand and maintain plant documentation; Batch Records, Cleaning Protocols, Equipment Use Logs, Equipment Status Tags and Labeling systems/Label generation.
  • Learn how to; properly weigh and scale operations, review batch records, inspect equipment, drum and package material, understand purging, follow labeling procedures, Read and understand sampling and analytical report forms, Use, clean and reset Niagara ceramic and Furan box filters, calibrate ph meters, set up and charge reactors, understand the scrubber operation and recharging, exercise proper grounding practices, control intermediates, accept raw materials, control finished products, use HHT’s and bar code system, conduct pressure filter operation, set up rectors for reflux, distillation and azeotrope, use and understand pumps, use TCM’s, use manual jacket services for reactor heating and cooling, proficiently document
  • Follow our dress code and personal protective equipment SOP
  • Perform all duties safely in accordance with; Rensselaer Safety Program, guidelines outlined by Good Manufacturing Practices for active pharmaceutical intermediates, Rensselaer Environmental Program.
  • Learn the buildings process and recommend and implement methods to increase the quality of products and/or service.
  • Participate in self-development activities.
  • Perform other related duties as may be reasonably assigned in the course of business.
Desired Qualifications
  • Knowledge and understanding of plant documentation such as batch records, cleaning protocols, equipment use logs, equipment status tags, and labeling systems/label generation
  • Associates or Bachelor's degree
  • Prior chemical experience

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$1.1B

Headquarters

Albany, New York

Founded

1991

Simplify Jobs

Simplify's Take

What believers are saying

  • Biologics segment expansion under Steve Lavezoli accelerates high-margin pharmaceutical outsourcing revenue growth.
  • Carterra partnership positions Curia to capture Pacific Northwest biotech demand in antibody discovery services.
  • Gerald Auer's CFO appointment signals M&A activity and potential strategic initiatives enhancing shareholder value.

What critics are saying

  • Pace Life Sciences acquisition of New Jersey lab erodes Curia's analytical testing capacity and revenue.
  • Larger CDMOs like Lonza and Catalent undercut Curia on biologics capacity, stealing biotech contracts.
  • FDA scrutiny on srRNA manufacturing defects from Replicate Bioscience Phase 1 triggers potential client exodus.

What makes Curia unique

  • Pioneer in self-replicating RNA manufacturing, demonstrated through Replicate Bioscience Phase 1 clinical trial support.
  • Integrated enzymatic doggybone DNA technology via Touchlight collaboration expands mRNA manufacturing competitive advantages.
  • End-to-end CDMO services from discovery through cGMP manufacturing differentiate Curia from specialized competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.

INACTIVE